January 2022: VBS Literature Update
Marlow E, Hassan T, Faia L, et al. Vitrectomy for symptomatic asteroid hyalosis. J Vitreoretin Dis. 2021;5(5):420-424.
Abstract by Vlad Matei, MD
Asteroid hyalosis (AH) is a common and benign degeneration consisting of calcium- and lipid-rich opacities, termed asteroid bodies (ABs), accumulating in the vitreous gel. Until recently, AH has been notable mainly for its tendency to obstruct the examiner’s view of the fundus; most eyecare professionals assume AH to be asymptomatic. However, Marlow et al. demonstrate that in a minority of patients AH can progress to a flagrant variant of symptomatic vitreous floaters, where not only visual function but also visual acuity can be affected.
In a retrospective case series from a large, tertiary-care, retina-only practice, the authors describe 6 patients who suffered acute vision loss attributed to AH and requiring pars plana vitrectomy (PPV), which was 23- or 25-gauge in all cases. All the 4 men and 2 women (median age 74 years, range 57-83) were affected in only one eye, which was pseudophakic in all but one case. In all 6 patients the vision loss coincided with a new partial or complete posterior vitreous detachment (PVD). The mean preoperative VA was 20/150, and it ranged from 20/25-20/2500, with the 20/2500 patient having 20/200 baseline vision due to dominant optic atrophy.
The mean postoperative VA was 20/35 (range 20/20-20/200) at a mean final follow-up interval of 13.5 months (minimum 2 months) postoperatively; most of the VA improvement took place by 1 month after PPV. Although there were no surgical complications, 4 of the 6 patients were found to have vitreoschisis intraoperatively, in keeping with prior literature suggesting that AH patients have delayed PVD onset and abnormally strong vitreoretinal adhesion.
As the onset of vision loss in this series seemed to occur in association with PVD progression, the authors echoed the hypothesis that vision loss in AH occurs because PVD shifts the distribution of the ABs anteriorly in the vitreous cavity, closer to the nodal point of the eye, since ABs do not develop in liquid vitreous or posterior to the posterior hyaloid membrane. Particularly impressive in the paper were the three individually described cases, in which the authors reported an AH-related VA decline from 20/30 to 20/200 in one case and an improvement from 20/200 to 20/20 postoperatively in another case.
Although this case series is very small, it is an important contribution to the vitreoretinal literature because it clearly demonstrates that AH, which is often assumed to be asymptomatic, can be responsible for a marked decrease in visual acuity that is reversible with PPV. Because AH is so common, yet rarely causes vision loss, vision loss due to AH should be a diagnosis of exclusion, especially if there is no evidence of at least partial PVD. A final take-home point from this paper is that AH patients may be more likely to have abnormally strong vitreoretinal attachment, so during PPV surgeons should consider making an extra effort to visualize residual posterior vitreous, such as by coating the hyaloid with triamcinolone, and more carefully searching for iatrogenic peripheral retinal breaks at the end of the case.
January 2022: VBS Literature Update
Marlow E, Hassan T, Faia L, et al. Vitrectomy for symptomatic asteroid hyalosis. J Vitreoretin Dis. 2021;5(5):420-424.
Abstract by Vlad Matei, MD
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and Vit Buckle Society. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Vlad Matei, MD
Rocky Mountain Retina Associates
Boulder, CO
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Vlad Matei, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences and Allergan.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve.
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!